Cargando…

Benefits of adjuvant treatment including trastuzumab in HER2-positive pT1a-bN0M0 breast cancer: a systematic review and meta-analysis

BACKGROUND: Although trastuzumab has been shown to be beneficial for treating patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, information regarding its benefits is limited to very low-risk cases with tumours ≤1 cm and without lymphatic metastases (pT1abN0). The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Hye Yoon, Shin, In-Soo, Rim, Chai Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154451/ https://www.ncbi.nlm.nih.gov/pubmed/32309334 http://dx.doi.org/10.21037/atm.2020.01.81

Ejemplares similares

For or against Adjuvant Trastuzumab for pT1a-bN0M0 Breast Cancer Patients with HER2-Positive Tumors: A Meta-Analysis of Published Literatures
por: Zhou, Qiong, et al.
Publicado: (2014)

Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study
por: Ali, Sanji, et al.
Publicado: (2022)

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
por: Sasada, Shinsuke, et al.
Publicado: (2023)

The Effectiveness of Postoperative Chemotherapy on pT1bN0 and pT2N0 Gastric Cancer Patients with Risk Factors: An International Dual-Center Analysis
por: Yang, Kun, et al.
Publicado: (2021)

HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort
por: Rouanet, Philippe, et al.
Publicado: (2014)

Is Adjuvant Chemotherapy Beneficial to All Patients With pT3N0M0 Stage Gastric Cancer?
por: Huang, Jiao-Bao, et al.
Publicado: (2021)

Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database
por: Hu, Guangfu, et al.
Publicado: (2020)

The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer
por: Gori, Stefania, et al.
Publicado: (2015)

Adjuvant therapy for HER2 positive pT1a-b pN0 breast cancer: A single center cohort study
por: Yang, Xuan, et al.
Publicado: (2022)

Adjuvant Chemotherapy in pT2N0M0 Gastric Cancer: Findings From a Retrospective Study
por: Mei, Yu, et al.
Publicado: (2022)

Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
por: Lluch-Gómez, J., et al.
Publicado: (2023)

Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer
por: Gori, Stefania, et al.
Publicado: (2015)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
por: McLaughlin, Shannon, et al.
Publicado: (2023)

Oncologic Benefit of Adjuvant Chemoradiation after D2 Gastrectomy: A Stepwise Hierarchical Pooled Analysis and Systematic Review
por: Rim, Chai Hong, et al.
Publicado: (2020)

Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer
por: Wang, Qi-Wei, et al.
Publicado: (2018)

PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
por: Pondé, Noam, et al.
Publicado: (2019)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
por: Loibl, Sibylle, et al.
Publicado: (2022)

Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy
por: Cao, Lu, et al.
Publicado: (2016)

Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
por: Sardesai, Sagar, et al.
Publicado: (2020)

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
por: Simoens, Steven, et al.
Publicado: (2021)

Exploration of prognostic factors and the value of adjuvant chemotherapy in T1a,bN0M0 triple-negative breast cancer: a prospective cohort study based on the SEER database
por: Wu, Junzhao, et al.
Publicado: (2022)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

First-in-human phase 0 study of (111)In-CHX-A”-DTPA trastuzumab for HER2 tumor imaging
por: Kurdziel, KA, et al.
Publicado: (2018)

Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study
por: Li, Junjie, et al.
Publicado: (2018)

Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
por: Hajjar, Ali, et al.
Publicado: (2019)

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
por: Genuino, Anne Julienne, et al.
Publicado: (2019)

How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?
por: Morganti, S., et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
por: Tran, Phuong T., et al.
Publicado: (2020)

Safety and efficacy of ultrasound-guided thermal ablation in treating T1aN0M0 and T1bN0M0 papillary thyroid carcinoma: A meta-analysis
por: Wang, Mei-Huan, et al.
Publicado: (2022)

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
por: Dang, Chau, et al.
Publicado: (2022)

Factors Associated with Nodal Upstaging in Clinical T1a-bN0M0 Non-Small Cell Lung Cancers
por: Tsai, Tung-Ming, et al.
Publicado: (2022)

Nomogram for Predicting Overall Survival and Assessing the Survival Benefit of Adjuvant Treatment in pT1-2N0M0 Triple-Negative Breast Cancer: A Surveillance, Epidemiology, and End Results-Based Study
por: Mao, Qixin, et al.
Publicado: (2022)

The role of adjuvant therapy in pT4N0 laryngectomized patients: Multicentric observational study
por: Mattioli, Francesco, et al.
Publicado: (2022)

Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
por: Firwana, Belal, et al.
Publicado: (2012)

The Role of Trastuzumab in Patients with HER2 Positive Small (pT1mi/a) Breast Cancers, a Multicenter Retrospective Study
por: Villasco, Andrea, et al.
Publicado: (2021)

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials
por: Viani, Gustavo A, et al.
Publicado: (2007)

Concurrent administration of trastuzumab and anthracyclines as adjuvant regimen for HER2-positive breast cancer: a randomised controlled trial
por: Shen, Songjie, et al.
Publicado: (2017)

Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis
por: Goldvaser, Hadar, et al.
Publicado: (2019)

Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis
por: Genuino, Anne Julienne, et al.
Publicado: (2019)

Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab
por: Jacquinot, Quentin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g81of5tepn7btqv21fnmicf50u